Aslam Farhan, Haque Attiya, Lee Veronica, Foody Joanne
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Patient Prefer Adherence. 2009 Nov 3;3:61-6. doi: 10.2147/ppa.s4201.
Cardiovascular disease (CVD) accounts for in excess of 930,000 deaths in the United States each year. Risk factors for CVD often co-exist. Studies estimate that over half of the hypertensive population also has dyslipidemia. Observational data suggest that fewer than 10% of patients attain recommended therapeutic targets for both conditions. A variety of patient, regimen and system characteristics have been associated with the risk for non-adherence. Poly-pharmacy and complex drug regimens are associated with poor patient adherence and thus the use of fixed-dose combination therapies, may improve adherence by reducing the pill burden. The fixed-dose combination of amlodipine/atorvastatin offers a convenient and effective approach to manage two important CVD risk factors. The combination of amlodipine/atorvastatin has a synergistic effect. The half-life of both agents facilitates once-daily dosing and both can be administered at any time of the day with or without food. Amlodipine/atorvastatin combined pill can be used to initiate both agents or patients can be switched directly from single-agent therapy with one or both agents. The convenience of single-pill amlodipine/atorvastatin has the potential to improve patient adherence and the management of cardiovascular risk in selected patients, thereby improving clinical outcomes.
在美国，心血管疾病（CVD）每年导致超过93万人死亡。CVD的风险因素常常并存。研究估计，超过一半的高血压患者同时患有血脂异常。观察数据表明，不到10%的患者能达到这两种病症的推荐治疗目标。多种患者、治疗方案和系统特征都与不依从风险相关。联合用药和复杂的药物治疗方案与患者依从性差有关，因此，使用固定剂量复方疗法可能通过减轻服药负担来提高依从性。氨氯地平/阿托伐他汀固定剂量复方制剂为管理两个重要的CVD风险因素提供了一种方便有效的方法。氨氯地平/阿托伐他汀组合具有协同作用。两种药物的半衰期便于每日一次给药，且两种药物均可在一天中的任何时间服用，无论是否进食。氨氯地平/阿托伐他汀复方制剂可用于起始两种药物治疗，或者患者可以直接从一种或两种药物的单药治疗转换过来。氨氯地平/阿托伐他汀单片制剂的便利性有可能提高特定患者的依从性并改善心血管风险的管理，从而改善临床结局。
